Michael Lees

Learn More
In this paper we describe an adaptive, optimistic synchronisation mechanism for the parallel discrete event simulation of agent-based systems. The mechanism uses the Sphere of Influence (SoI) of an event (the region of the shared simulation state read or written to by the event) to define an adaptive metric which can be used with a throttling mechanism such(More)
In this paper we discuss the distributed simulation of agent-based systems in HLA. Using the SIM AGENT toolkit and the Tileworld scenario as an example, we present a design proposal showing how the HLA can be used to distribute a SIM AGENT simulation with different agents being simulated by different federates. We outline the changes necessary to the SIM(More)
This paper looks at the history and development of an agent testbed called Tileworld. It defines the original testbed and documents its gradual development up to its current form. It also introduces some of the experiments performed using Tileworld and their results. It concludes with a comparison of Tileworld with other agent testbeds and a look at agent(More)
OBJECTIVE Deep vein thrombosis and pulmonary embolism - together referred to as venous thromboembolism (VTE) - result in a major burden on healthcare systems. However, to the authors' knowledge no comprehensive review of the economic burden of VTE has so far been published. METHODS A literature search was carried out to identify references published in(More)
This study aimed to evaluate the cost-effectiveness of prophylaxis with rivaroxaban vs. enoxaparin in the prevention of venous thromboembolism (VTE) after total hip replacement (THR) and total knee replacement (TKR) from the perspective of the Canadian healthcare system. A model was developed that included both acute VTE (represented as a decision tree) and(More)
In this paper we outline an approach to the distributed simulation of agent-based systems using the SIM AGENT toolkit and the High Level Architecture (HLA) simulator interoperability framework. Using a simple Tileworld scenario as an example, we show how the HLA can be used to flexibly distribute a SIM AGENT simulation with different agents being simulated(More)
BACKGROUND Chronic hepatitis B (CHB) is associated with a significant burden of illness and treatment involves substantial health-care costs. This study estimates clinical outcomes and cost-effectiveness of lamivudine compared with other treatment scenarios for CHB, from an Australian health-care provider perspective. METHODS A two-step modeling approach(More)
In two recent randomised trials, gemcitabine plus cisplatin (Gem/Cis) was found to be at least as effective as vinorelbine plus cisplatin (Vin/Cis), paclitaxel plus cisplatin (Pac/Cis), paclitaxel plus carboplatin (Pac/Carbo), or docetaxel plus cisplatin (Doc/Cis) in patients with advanced non-small cell lung cancer (NSCLC). In cost-minimisation analyses of(More)